Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Relmada Therapeutics, Inc. RLMD NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
63/100
4/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.00
+25.2%

Relmada Therapeutics, Inc. (RLMD) is a Biotechnology company in the Healthcare sector, currently trading at $7.19. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is RLMD = $9 (+25.2% upside).

Valuation: RLMD trades at a trailing Price-to-Earnings (P/E) of -8.5 (S&P 500 average ~25).

Net income is $57M (loss), growing at +28.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $87M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 14.62 (strong liquidity). Debt-to-assets is 0%. Total assets: $94M.

Analyst outlook: 5 / 8 analysts rate RLMD as buy (63%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 67/100 (Pass), Income ?/100 (Fail).

$9.00
▲ 25.17% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Relmada Therapeutics, Inc., the average price target is $9.00, with a high forecast of $10.00, and a low forecast of $8.00.
Highest Price Target
$10.00
Average Price Target
$9.00
Lowest Price Target
$8.00

RLMD SharesGrow Score Overview

75/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 67/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RLMD

✓
VALUE Pass
75/100
RLMD trades at a trailing Price-to-Earnings (P/E) of -8.5 (S&P 500 average ~25). Forward PEG -0.33 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $9, implying +25.2% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
RLMD: +0%/yr revenue is, +28.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet RLMD: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 14.62 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
RLMD: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
67/100
Analyst outlook: 5 / 8 analysts rate RLMD as buy (63%). Analyst consensus target is $9 (+25.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.243-7.51
Volume1.42M
Avg Volume (30D)1.66M
Market Cap$527.27M
Beta (1Y)0.72
Share Statistics
EPS (TTM)-1.45
Shares Outstanding$39.48M
IPO Date2014-06-20
Employees17
CEOSergio Traversa
Financial Highlights & Ratios
EBITDA$-59.1M
Net Income$-57.39M
Operating Income$-59.1M
Total Cash$93.01M
Net Debt$-3.5M
Total Assets$94M
Price / Earnings (P/E)-5
Analyst Forecast
1Y Price Target$9.00
Target High$10.00
Target Low$8.00
Upside+25.2%
Rating ConsensusBuy
Analysts Covering8
Buy 63% Hold 25% Sell 13%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS75955J4022

Price Chart

Track all markets on TradingView
RLMD
Relmada Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.24 52WK RANGE 7.51

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 CYTK
CYTK
Cytokinetics, Incorporated
$66.35
-0.55%
 NAMS
NAMS
NewAmsterdam Pharma Company N.V.
$34.44
-4.99%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 DYN
DYN
Dyne Therapeutics, Inc.
$19.81
+4.26%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
 FUSN
FUSN
Fusion Pharmaceuticals Inc.
$21.55
+0.14%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message